#	Pagina
attuale pagina	/open-h2020/projects/217460/index.html

Opendata, web and dolomites

SMR SIGNED

Stroke Management through RGTA®: SMR

Total Cost €

EC-Contrib. €

Partnership

Views

SMR project word cloud

Explore the words cloud of the SMR project. It provides you a very rough idea of what is the project "SMR" about.

insult hours route showed registration focal transient cerebral sulphates preclinical 39 eligible rodent patients 48 extracellular infarction rgta reproduce urgent improvement benefit 2nd ischemia stage introduction indication persisted recovery thrombectomy endogenous matrix molecules acute positive translational thrombolysis neuroprotective absolutely sensorial stages interestingly networks macro synthetic treatment otr41h heparan demonstrated elicited chronic ready quick administration reg alternative damage ischemic clinical smr live outcomes animals brain countries stroke medical translate validation 6 mimicking models device market experimental functional biological handicaps model industrialized polysaccharides few cells volume death solution motor innovation injectable beneficial

Project "SMR" data sheet

The following table provides information about the project.

Coordinator	ORGANES TISSUS REGENERATION REPARATION REMPLACEMENT Organization address address: RUE FRANCAISE 4 city: PARIS postcode: 75001 website: www.otr3.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	France [FR]
Total cost	3˙404˙200 €
EC max contribution	2˙382˙940 € (70%)
Programme	1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
Code Call	H2020-SMEInst-2018-2020-2
Funding Scheme	SME-2
Starting year	2018
Duration (year-month-day)	from 2018-10-01 to 2022-07-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	ORGANES TISSUS REGENERATION REPARATION REMPLACEMENT ORGANES TISSUS REGENERATION REPARATION REMPLACEMENT Organization address address: RUE FRANCAISE 4 city: PARIS postcode: 75001 website: www.otr3.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (PARIS)	coordinator	2˙382˙940.00

Map

Project objective

Stroke is the 2nd cause of death and major handicaps in industrialized countries. At present, the only available treatment for ischemic stroke are thrombolysis and thrombectomy. However, very few patients are eligible, and it is therefore absolutely urgent to find an alternative. RGTA® are synthetic polysaccharides, mimicking endogenous macro-molecules called heparan sulphates, that make up the biological networks in which our cells live and reproduce: the extracellular matrix. We have recently investigated the neuroprotective potential of a novel specific RGTA® (OTR41H-1) at the preclinical level using a rodent model of transient focal cerebral ischemia The i.v. administration of OTR41H-1 elicited a reduction of 39,6% of the volume of infarction at 48 hours following the insult. Interestingly, this RGTA®-induced reduction of brain damage persisted up to the chronic stage and RGTA®-treated animals showed a significant improvement of functional recovery (motor and sensorial) when compared to control animals. Translational stroke studies in rodent models have thus already demonstrated the beneficial effects of RGTA® in acute phase and the project is now ready for next stages of its route to market introduction, including clinical validation and product registration. The objective of the SMR project is to translate experimental findings into medical innovation, leading to a quick benefit for stroke patients. Positive outcomes of the project will lead rapidly to a EU medical device registration of OTR41H-1 injectable solution and its market introduction in Europe for the stroke indication.

Publications

List of publications.
year	authors and title	journal	last update
2018	Yacine Khelif, JÃ©rÃ´me Toutain, Marie-Sophie Quittet, Sandrine Chantepie, Xavier Laffray, Samuel Valable, Didier Divoux, Fernando Sineriz, Emanuelle Pascolo-Rebouillat, Dulce Papy-Garcia, Denis Barritault, Omar Touzani, Myriam Bernaudin A heparan sulfate-based matrix therapy reduces brain damage and enhances functional recovery following stroke published pages: 5814-5827, ISSN: 1838-7640, DOI: 10.7150/thno.28252	Theranostics 8/21	2020-03-05

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SMR" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SMR" are provided by the European Opendata Portal: CORDIS opendata.